Industry News
Pharmaceutical Industry News
Suarez will return to the U.S. as…
Suarez will return to the U.S. as SVP and president, head of the U.S. biopharmaceuticals business unit, after five years posted in Madrid as head of the company's Spain division.
Mind Medicine has altered its…
Mind Medicine has altered its state, rebranding as Definium Therapeutics ahead of a series of phase 3 data drops on its lead psychedelic drug candidate.
Acuitas Therapeutics shelled out…
Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA Technologies & Therapeutics in a move to scale the latter's operations around high-end RNA constructs used to
Novo Nordisk has begun a vital…
Novo Nordisk has begun a vital year for its weight-loss franchise with a push to understand how obesity hits differently depending on factors such as culture, gender and generation. The research informed an exhibit in
Salesforce’s Mark Sullivan…
Salesforce’s Mark Sullivan explains why trust, data discipline and human oversight will determine who wins in an agent-driven future.
Though Gilead Sciences made waves…
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting treatment for the viral infection. Now,
Viking Therapeutics and Aspen…
Viking Therapeutics and Aspen Neuroscience have both stepped up their commercialization planning, each tapping leaders with resumes spanning the likes of Amgen, Eli Lilly, Merck and GSK to oversee launch preparations for their obesity and
The FDA is apparently not charmed…
The FDA is apparently not charmed by the mischievous “Lipid Lurkers” in an Esperion Therapeutics commercial for cholesterol-lowering drug Nexlizet.
Under the agreement, Genesis is…
Under the agreement, Genesis is responsible for marketing Daiichi's 2023-approved acute myeloid leukemia med Vanflyta in 13 European countries.
Two investigational…
Two investigational cardiometabolic drugs from Eli Lilly stand out in Clarivate's annual Drugs to Watch report. Johnson & Johnson also has two drugs featured on the data analytics company's 2026 list.
Dispelling 9 Myths About Women’s Health
When it comes to heart health, immunity, reproductive health and more, misconceptions abound.
In this week’s episode of “The…
In this week’s episode of "The Top Line," Fierce Pharma’s Fraiser Kansteiner sits down with three biopharma CEOs to unpack what defined 2025 and what comes next.
Forget about Herceptin. There’s…
Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz Pharmaceuticals’ bispecific Ziihera—at least according to two experts.
Bayer has filed lawsuits against…
Bayer has filed lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual property developed three decades ago. Bayer filed separate complaints against Moderna, Johnson & Johnson and one against Pfizer and BioNTech.
M+C Saatchi North America is…
M+C Saatchi North America is turning to a longtime pharma pro to serve as its inaugural medical advisor.
All together, the top 10 spenders…
All together, the top 10 spenders shelled out $285.8 million to air their TV drug ads throughout December.
While policy shifts and leadership…
While policy shifts and leadership shakeups at institutions like the FDA dominated headlines in 2025, drugmakers would do well to sift through the noise and remain focused on what they do best—developing novel medicines to
AstraZeneca, chasing GSK’s rival…
AstraZeneca, chasing GSK's rival Benlysta, is looking to bring a subcutaneous version of its 2021-approved Saphnelo to more patients after nabbing a European nod last month.
The Centers for Disease Control…
The Centers for Disease Control and Prevention has upended the immunization schedule for children in the U.S., eliminating six of the 17 vaccines that were previously recommended to protect them from disease.
After shepherding the company…
After shepherding the company through its first approval and the successful launch of blockbuster autoimmune drug Vyvgart, argenx co-founder and chief executive Tim Van Hauwermeiren is passing the reins to the Dutch drugmaker’s operating chief.